Combination methotrexate and gefitinib: A potential medical treatment for inoperable nontubal ectopic pregnancy.
gefitinib
interstitial ectopic pregnancy
methotrexate
nontubal ectopic pregnancy
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
13
09
2019
accepted:
14
11
2019
pubmed:
10
12
2019
medline:
15
12
2020
entrez:
10
12
2019
Statut:
ppublish
Résumé
Nontubal ectopic pregnancies present as a therapeutic challenge. A 35-year-old primigravida at 7 weeks gestation had a live interstitial ectopic pregnancy and contraindications to surgery. The patient was treated with a multidose methotrexate regimen combined with oral gefitinib (250 mg daily for 7 days). The peak human chorionic gonadotropin (hCG) of the patient was recorded at 19 510 IU/L and began declining from day 4 of combination therapy (day 6 of initial treatment). Successful resolution of the ectopic was demonstrated by cessation of the fetal heart by day 15 and hCG falling to 23 IU/L by day 42. A 10-year review of all nontubal ectopic pregnancies treated with methotrexate identified 46 cases, which had a comparable time to resolution to combination therapy. However, for cases where cardiac activity was present, the median time to resolution following methotrexate treatment was 64 days (47-87 days), 22 days longer than combination therapy. Combination therapy may provide a safe medical treatment for inoperable nontubal ectopic pregnancy.
Substances chimiques
Abortifacient Agents, Nonsteroidal
0
Gefitinib
S65743JHBS
Methotrexate
YL5FZ2Y5U1
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
531-535Informations de copyright
© 2019 Japan Society of Obstetrics and Gynecology.
Références
Dolinko AV, Vrees RA, Frishman GN. Non-tubal ectopic pregnancies: Overview and treatment via local injection. J Minim Invasive Gynecol 2018; 25: 287-296.
Ferretti C, Bruni L, Dangles-Marie V, Pecking AP, Bellet D. Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Hum Reprod Update 2007; 13: 121-141.
Capmas P, Fernandez H. Effectiveness of gefitinib in combination with methotrexate in the treatment of ectopic pregnancy. Int J Womens Health 2015; 7: 673-676.
Skubisz MM, Horne AW, Johns TG et al. Combination gefitinib and methotrexate compared with methotrexate alone to treat ectopic pregnancy. Obstet Gynecol 2013; 122: 745-751.
Skubisz MM, Tong S, Doust A et al. Gefitinib and methotrexate to treat ectopic pregnancies with a pre-treatment serum hcg 1000-10,000iu/l: Phase ii open label, single arm multi-centre trial. EBioMedicine 2018; 33: 276-281.
Horne AW, Skubisz MM, Tong S et al. Combination gefitinib and methotrexate treatment for non-tubal ectopic pregnancies: A case series. Hum Reprod 2014; 29: 1375-1379.
Liu Y, Zhang Y, Feng G et al. Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non-small cell lung cancer: A network meta-analysis. Exp Ther Med 2017; 14: 4017-4032.
Parker VL, Srinivas M. Non-tubal ectopic pregnancy. Arch Gynecol Obstet 2016; 294: 19-27.
Alalade AO, Smith FJE, Kendall CE, Odejinmi F. Evidence-based management of non-tubal ectopic pregnancies. J Obstet Gynaecol 2017; 37: 982-991.
Hunt SP, Talmor A, Vollenhoven B. Management of non-tubal ectopic pregnancies at a large tertiary hospital. Reprod Biomed Online 2016; 33: 79-84.